Tipsheet
What matters at India’s listed companies
Earnings · Agriculture · Micro cap

Genomic Valley Biotech profit shrinks 91% as revenue halves

The biotech's annual revenue fell to ₹26.75 lakhs, while net profit collapsed to ₹3.03 lakhs.


Mkt cap₹8.11 cr
ROE9.13%
Debt / eq.0.00
91% Year-on-year net profit decline

What's new

  • FY26 revenue fell 68% to ₹26.75 lakhs from ₹84.84 lakhs in FY25.
  • Net profit dropped 91% to ₹3.03 lakhs from ₹35.6 lakhs.
  • The board appointed Navjyoti Kumar Jha as internal auditor for FY27.

Why this matters

Profit fell far faster than revenue, pointing to a rigid cost base. For a company with just ₹26.75 lakhs in annual sales, the margin compression leaves almost no buffer.

What we're watching

  • Any management commentary on the cause of the 68% revenue drop.
  • Whether the new auditor highlights control weaknesses or a going-concern risk.
  • Any new contracts or orders to rebuild the top line.

The full read

Genomic Valley Biotech's annual results read like a business in retreat. Revenue fell 68% to ₹26.75 lakhs. Net profit dropped to ₹3.03 lakhs from ₹35.6 lakhs, a decline far steeper than the top line. That points to a cost structure that didn't flex with the sales drop. For a company this small, such a sharp contraction raises immediate questions about its operational runway. The board also named a new internal auditor. That's standard procedure, but it takes on more weight when the underlying business is shrinking this fast. The numbers paint a picture of a company struggling to maintain its scale.

Questions answered

How severe was the revenue decline?
Annual revenue fell 68% year-on-year, dropping to ₹26.75 lakhs from ₹84.84 lakhs.
Why is the profit drop more worrying than the revenue drop?
Profit fell 91%, far steeper than the 68% revenue decline, indicating that fixed costs did not shrink with sales.
What was the board's other action during the meeting?
The board appointed Navjyoti Kumar Jha as internal auditor for the 2026-27 financial year, a standard compliance step.
What is the scale of the company's operations?
With FY26 revenue of ₹26.75 lakhs, Genomic Valley is a very small operation. The prior year's ₹84.84 lakhs was also modest.
Mentioned: Navjyoti Kumar Jha · FY26 · FY25
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.